Abstract
Tuberculosis is a chronic bacterial infection caused by Mycobacterium tuberculosis. The emergence of multidrug resistant tuberculosis has made the fight against tuberculosis more difficult. Bedaquiline is a very promising drug candidate for the treatment of tuberculosis. It has been reported that the MIC90 value of bedaquiline was remarkably low (0.06 µg/mL), effectively inhibiting ATP synthase of mycobacteria. Potential drawbacks of bedaquiline include inhibition of the cardiac potassium channel with human Ether-à-go-go-Related Gene (hERG); with the concomitant risk of cardiac toxicity. Hence, developing new drugs with better activity and/or fewer side effects is required. In this study, we investigated in silico pharmacokinetics analysis and molecular docking methods into bedaquiline analogs selected having similarity with Bedaquiline to analyze their binding modes and their stability within the ATP synthase active site. The molecular docking results show that molecule 5 with a benzofuran group at the position R3 and the pyridine ring at position R2 with side chains interacts with residues of active sites in the same way as bedaquiline, with a binding energy of -7.12 kcal/mol. From this structural analysis the change of the phenyl cycle of bedaquiline by pyridine with a side chain in the C5 position, allows the improvement of the interaction with the hydrophobic pocket of the active site, with a significant reduction in inhibition of hERG channel potassium current (IC50 > 10 µM) compared with bedaquiline (IC50 = 1.6 µM). As well as the change of the Naphthalene unit by a heterocyclic aromatic group (Benzofuran) allows the improvement of the inhibitory activity (MIC90) against the M strain tb-H37Rv. The study opens up a new strategy for the development of drugs for treating tuberculosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
WHO. Global Tuberculosis Report (2018)
Espinal, M.A.: The global situation of MDR-TB. Tuberculosis 83(1–3), 44–51 (2003). https://doi.org/10.1016/S1472-9792(02)00058-6
Cox, M.D.E., Laessig, K.: FDA approval of bedaquiline—the benefit-risk balance for drug-resistant tuberculosis. New Engl. J. Med. 371, 689–691 (2014)
Andries, K., et al.: A diarylquinoline drug active on the ATP synthase of mycobacterium tuberculosis. Science 307(5707), 223–227 (2005). https://doi.org/10.1126/science.1106753
Walker, J.E.: The ATP synthase: the understood, the uncertain and the unknown. Biochem. Soc. Trans. 41(1), 1–16 (2013). https://doi.org/10.1042/BST20110773
Boyer, P.: The ATP synthase—a splendid molecular machine. Ann. Rev. Biochem. 66(1), 717–749 (1997). https://doi.org/10.1146/annurev.biochem.66.1.717
von Ballmoos, C., Wiedenmann, A., Dimroth, P.: Essentials for ATP synthesis by F 1 F 0 ATP synthases. Annu. Rev. Biochem. 78(1), 649–672 (2009). https://doi.org/10.1146/annurev.biochem.78.081307.104803
Haagsma, A.C., et al.: Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS ONE 6(8), 1–7 (2011). https://doi.org/10.1371/journal.pone.0023575
Sutherland, H.S., et al.: Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles. Bioorganic Med. Chem. 26(8), 1797–1809 (2018). https://doi.org/10.1016/j.bmc.2018.02.026
Tong, A.S.T., et al.: 6-cyano analogues of bedaquiline as less lipophilic and potentially safer diarylquinolines for tuberculosis. ACS Med. Chem. Lett. 8(10), 1019–1024 (2017). https://doi.org/10.1021/acsmedchemlett.7b00196
Preiss, L., et al.: Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline. Sci. Adv. 1(4), 1–8 (2015). https://doi.org/10.1126/sciadv.1500106
Allouche, A.: Software news and updates gabedit — a graphical user interface for computational chemistry softwares. J. Comput. Chem. 32, 174–182 (2012). https://doi.org/10.1002/jcc
Kim, S., et al.: PubChem substance and compound databases. Nucleic Acids Res. 44(D1), D1202–D1213 (2016). https://doi.org/10.1093/nar/gkv951
Hanwell, M., Curtis, D., Lonie, D., Vandermeersch, T., Zurek, E., Hutchison, G.: Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J. Cheminf. 4(1), 1–17 (2012). https://doi.org/10.1186/1758-2946-4-17
Daina, A., Michielin, O., Zoete, V.: SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 1–13 (2017). https://doi.org/10.1038/srep42717
Benet, L.Z., Hosey, C.M., Ursu, O., Oprea, T.I.: BDDCS, the Rule of 5 and drugability. Adv. Drug Deliv. Rev. 101, 89–98 (2016). https://doi.org/10.1016/j.addr.2016.05.007
Yuan, S., Chan, H.C.S., Hu, Z.: Using PyMOL as a platform for computational drug design. Wiley Interdiscip. Rev. Comput. Mol. Sci. 7(2), 1–10 (2017). https://doi.org/10.1002/wcms.1298
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this paper
Cite this paper
Maurady, A., M’guil, M., Sadoq, BE., Eslami, G., Britel, M.R. (2022). Molecular Docking Study of Selected Molecules as Novel Targets for ATPase of Mycobacterium Tuberculosis Inhibitors. In: Kacprzyk, J., Balas, V.E., Ezziyyani, M. (eds) Advanced Intelligent Systems for Sustainable Development (AI2SD’2020). AI2SD 2020. Advances in Intelligent Systems and Computing, vol 1417. Springer, Cham. https://doi.org/10.1007/978-3-030-90633-7_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-90633-7_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-90632-0
Online ISBN: 978-3-030-90633-7
eBook Packages: Intelligent Technologies and RoboticsIntelligent Technologies and Robotics (R0)